These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26702926)

  • 1. Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
    Lambert-Niclot S; George EC; Pozniak A; White E; Schwimmer C; Jessen H; Johnson M; Dunn D; Perno CF; Clotet B; Plettenberg A; Blaxhult A; Palmisano L; Wittkop L; Calvez V; Marcelin AG; Raffi F;
    J Antimicrob Chemother; 2016 Apr; 71(4):1056-62. PubMed ID: 26702926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
    Grinsztejn B; Hughes MD; Ritz J; Salata R; Mugyenyi P; Hogg E; Wieclaw L; Gross R; Godfrey C; Cardoso SW; Bukuru A; Makanga M; Faesen S; Mave V; Wangari Ndege B; Nerette Fontain S; Samaneka W; Secours R; van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Avihingsanon A; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC;
    Lancet HIV; 2019 Sep; 6(9):e588-e600. PubMed ID: 31371262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D
    D2EFT Study Group
    Lancet HIV; 2024 Jul; 11(7):e436-e448. PubMed ID: 38788744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
    Raffi F; Babiker AG; Richert L; Molina JM; George EC; Antinori A; Arribas JR; Grarup J; Hudson F; Schwimmer C; Saillard J; Wallet C; Jansson PO; Allavena C; Van Leeuwen R; Delfraissy JF; Vella S; Chêne G; Pozniak A;
    Lancet; 2014 Nov; 384(9958):1942-51. PubMed ID: 25103176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
    Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
    Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year follow-up of patients enrolled in the NEAT 001/ANRS 143 randomized clinical trial: NEAT 001/ANRS 143 LONG TERM study.
    Raffi F; Gaultier A; Pozniak A; Molina JM; Jessen H; Antinori A; Soria A; Cavellec M; Le Thuaut A; Ningre M; de Wit S
    J Antimicrob Chemother; 2020 Jun; 75(6):1618-1622. PubMed ID: 32211883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.
    Bernardino JI; Mocroft A; Mallon PW; Wallet C; Gerstoft J; Russell C; Reiss P; Katlama C; De Wit S; Richert L; Babiker A; Buño A; Castagna A; Girard PM; Chene G; Raffi F; Arribas JR;
    Lancet HIV; 2015 Nov; 2(11):e464-73. PubMed ID: 26520926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
    Lennox JL; Landovitz RJ; Ribaudo HJ; Ofotokun I; Na LH; Godfrey C; Kuritzkes DR; Sagar M; Brown TT; Cohn SE; McComsey GA; Aweeka F; Fichtenbaum CJ; Presti RM; Koletar SL; Haas DW; Patterson KB; Benson CA; Baugh BP; Leavitt RY; Rooney JF; Seekins D; Currier JS;
    Ann Intern Med; 2014 Oct; 161(7):461-71. PubMed ID: 25285539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
    La Rosa AM; Harrison LJ; Taiwo B; Wallis CL; Zheng L; Kim P; Kumarasamy N; Hosseinipour MC; Jarocki B; Mellors JW; Collier AC;
    Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.
    Dickinson L; Gurjar R; Stöhr W; Bonora S; Owen A; D'Avolio A; Cursley A; Molina JM; Fäetkenheuer G; Vandekerckhove L; Di Perri G; Pozniak A; Richert L; Raffi F; Boffito M;
    J Antimicrob Chemother; 2020 Mar; 75(3):628-639. PubMed ID: 31754703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation.
    Sahloff EG; Duggan JM
    Ann Pharmacother; 2019 Jan; 53(1):50-55. PubMed ID: 30047788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An apparent paradox: resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy.
    Geretti AM; Abdullahi A; Mafotsing Fopoussi O; Bonnett L; Fokom Defo V; Moudourou S; Fokam J; Kouanfack C; Torimiro J
    J Antimicrob Chemother; 2019 Oct; 74(10):3011-3015. PubMed ID: 31299067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial.
    Eholie SP; Ekouevi DK; Chazallon C; Charpentier C; Messou E; Diallo Z; Zoungrana J; Minga A; Ngom Gueye NF; Hawerlander D; Dembele F; Colin G; Tchounga B; Karcher S; Le Carrou J; Tchabert-Guié A; Toni TD; Ouédraogo AS; Bado G; Toure Kane C; Seydi M; Poda A; Mensah E; Diallo I; Drabo YJ; Anglaret X; Brun-Vezinet F;
    Lancet HIV; 2024 Jun; 11(6):e380-e388. PubMed ID: 38740027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.
    Stella-Ascariz N; Montejano R; Rodriguez-Centeno J; Alejos B; Schwimmer C; Bernardino JI; Rodes B; Allavena C; Hoffmann C; Gisslén M; de Miguel R; Esteban-Cantos A; Wallet C; Raffi F; Arribas JR;
    J Infect Dis; 2018 Oct; 218(10):1523-1530. PubMed ID: 29982509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials.
    Lathouwers E; Weinsteiger S; Baugh B; Ghys A; Jezorwski J; Mohsine EG; Van Landuyt E; De Meyer S
    J Med Virol; 2021 Jun; 93(6):3985-3990. PubMed ID: 33300183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
    Lathouwers E; Wong EY; Brown K; Baugh B; Ghys A; Jezorwski J; Mohsine EG; Van Landuyt E; Opsomer M; De Meyer S;
    AIDS Res Hum Retroviruses; 2020 Jan; 36(1):48-57. PubMed ID: 31516033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.
    Pulido F; Ribera E; Lagarde M; Pérez-Valero I; Palacios R; Iribarren JA; Payeras A; Domingo P; Sanz J; Cervero M; Curran A; Rodríguez-Gómez FJ; Téllez MJ; Ryan P; Barrufet P; Knobel H; Rivero A; Alejos B; Yllescas M; Arribas JR;
    Clin Infect Dis; 2017 Nov; 65(12):2112-2118. PubMed ID: 29020293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).
    Taiwo B; Zheng L; Gallien S; Matining RM; Kuritzkes DR; Wilson CC; Berzins BI; Acosta EP; Bastow B; Kim PS; Eron JJ;
    AIDS; 2011 Nov; 25(17):2113-22. PubMed ID: 21857490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.